ArticleJournal of ovarian research2026
Stage-, dose- and course-dependent disruption of mice fetal ovarian development following prenatal dexamethasone exposure.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDexamethasone, a synthetic glucocorticoid, is widely used during pregnancy to prevent preterm infant respiratory distress syndrome. While our prior work established that multiple courses of prenatal dexamethasone exposure (PDE) impair offspring ovarian function with transgenerational effects, the specific impacts of exposure stages, doses, and courses remain poorly defined. MATERIALS AND
methodsPregnant Kunming mice were treated with dexamethasone during mid-late gestation (GD14-15) or late gestation (GD16-17) with low/moderate/high doses, either as a single course or as two consecutive courses. Fetal ovaries were collected at GD18 to assess morphology, cell proliferation/apoptosis, steroidogenic markers, and oocyte-development genes; network toxicology was used to infer candidate pathways.
resultsPDE disrupted fetal ovarian morphogenesis, characterized by premature germ-cell nest breakdown, reduced proliferation and increased apoptosis. PDE at different stages, doses and courses can increase ovarian steroid synthesis (SF1\StAR\CYP11A1\Hsd3b\CYP19A1) while suppressing oocyte and folliculogenesis genes (NOBOX\Figlα\Sohlh2\Bmp15\Gdf9). These effects are stage-, dose- and course-dependent, with the most obvious toxicity resulting from exposure in the mid-late stages of pregnancy, at high doses and in a single course. Network toxicology and qPCR revealed the NR3C1-MAPK14-IL6 axis: IL6 was positively correlated with proliferation and oocyte development markers, while NR3C1/MAPK14 was associated with apoptosis and steroidogenesis.
conclusionsThis study provides experimental evidence for guiding clinical "precision medicine" and effectively assessing the risk of fetal ovarian developmental toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.